About the Company
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IDRA News
Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership
Separately, TheStreet Ratings team rates IDERA PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: We rate IDERA ...
Idera Acquires Bootstrapped Data Visualisation Platform FusionCharts
As a part of the deal, FusionCharts will now be a part of Idera Inc’s developer tools business unit, which already includes software productivity brands like Embarcadero, Lansa, Sencha ...
Armata Pharmaceuticals Inc ARMP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Kelvin Neu's Net Worth
Kelvin Neu does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Prelude Therapeutics Inc, XOMA ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
EGRX Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care ...
Cyclacel Pharmaceuticals, Inc. (CYCC)
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections ...
KalVista Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
SYRS Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene ...
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...
Loading the latest forecasts...